NSCLC患者来源肿瘤异种移植物的激酶组学分析证实其保真性并揭示可靶向通路
该研究对81例NSCLC手术样本进行PDTX建模,成瘤率33%,成瘤与不良临床结局相关。基因组和激酶组分析显示PDTX保留了原发肿瘤特征,TKI反应或符合遗传状态或揭示单基因组指纹无法预测的靶点,支持PDTX作为生物标志物发现和治疗算法优化的临床前工具。
要点
- PDTX成瘤率33%,成功成瘤与不良临床结局更相关。
- PDTX保留原发肿瘤的激酶组学特征,TKI反应可符合或超出遗传状态预测。
- 联合基因组与激酶组分析可识别患者特异性可靶向通路。
核心结论
- PDTX大多与原发NSCLC相似,联合基因组和激酶组分析可识别患者特异性可靶向通路,证实PDTX是生物标志物识别和治疗算法优化的临床前工具。
研究设计与样本
- 将81例NSCLC手术样本的新鲜肿瘤碎片植入Nod/Scid/Gamma小鼠,比较移植瘤与原发标本的形态学、免疫组化、基因突变分析和激酶活性谱。
- 使用PamGene肽微阵列平台测试四种酪氨酸和丝氨酸/苏氨酸激酶抑制剂对原发肿瘤和PDTX裂解物的反应。
主要发现
- 成瘤率为33%,成功成瘤与不良临床结局更相关。
- 基因组谱识别热点突变,其中一些最初在供体样本中未检测到。
- 激酶组分析显示原发肿瘤特征在PDTX中保留,个体PDTX系的TKI反应或符合遗传状态预期,或揭示单基因组指纹无法预测的合适靶点。
临床怎么用
- PDTX可保留原发NSCLC的激酶组学特征,可用于临床前识别患者特异性可靶向通路。
- 联合基因组与激酶组分析有助于发现单基因组指纹无法预测的TKI反应靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: High fidelity between non-small cell lung cancer (NSCLC) primary tumours and patient-derived tumour xenografts (PDTXs) is of paramount relevance to spur their application. Extensive proteomic and kinomic analysis of these preclinical models are missing and may inform about their functional status, in terms of phosphopeptides and hyperactive signalling pathways. METHODS: We investigated tumour xenografts derived from patients with NSCLC to identify hyperactive signalling pathways. Fresh tumour fragments from 81 NSCLC surgical samples were implanted in Nod/Scid/Gamma mice, and engrafted tumours were compared with primary specimens by morphology, immunohistochemistry, gene mutation analyses, and kinase activity profiling. Four different tyrosine and serine/threonine kinase inhibitors were tested against primary tumour and PDTX lysates using the PamGene peptide microarray platform. RESULTS: The engraftment rate was 33%, with successful engraftment being more associated with poor clinical outcomes. Genomic profiles led to the recognition of hotspot mutations, some of which were initially undetected in donor samples. Kinomic analyses showed that characteristics of primary tumours were retained in PDTXs, and tyrosine kinase inhibitors (TKIs) responses of individual PDTX lines were either expected, based on the genetic status, or alternatively defined suitable targets unpredictable by single-genome fingerprints. CONCLUSIONS: Collectively, PDTXs mostly resembled their parental NSCLC. Combining genomic and kinomic analyses of tumour xenografts derived from patients with NSCLC, we identified patients' specific targetable pathways, confirming PDTXs as a preclinical tool for biomarker identification and therapeutic algorithm'' improvement.
引用
- Tabbò F, Guerrera F, van den Berg A, et al. Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways. Eur J Cancer. 2020. PMID: 33316635. doi:10.1016/j.ejca.2020.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。